Characteristics of and Treatment Strategies for Advanced EGFR-Mutant NSCLC With Concomitant BRAF Variations

INTRODUCTION: BRAF variants were reported resistant mechanisms to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant NSCLC. Nevertheless, characteristics and subsequent treatment strategies of such patients remain unclear. METHODS: From October 2016 to May 2020, patients with advanced NSCLC for w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Xue-Wu, Deng, Jia-Yi, Xu, Chong-Rui, Chen, Zhi-Hong, Zhu, Dong-Qin, Wu, Qian, Zhang, Xu-Chao, Wu, Yi-Long, Zhou, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250018/
https://www.ncbi.nlm.nih.gov/pubmed/35789792
http://dx.doi.org/10.1016/j.jtocrr.2022.100348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250018/
https://www.ncbi.nlm.nih.gov/pubmed/35789792
http://dx.doi.org/10.1016/j.jtocrr.2022.100348

Ejemplares similares